Literature DB >> 8918488

Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy.

N W Lemmers1, M E Gels, D T Sleijfer, J T Plukker, W T van der Graaf, Z J de Langen, J H Droste, H S Koops, H J Hoekstra.   

Abstract

PURPOSE: Venous access ports (VAPs) can be used to administer polychemotherapy to patients with malignancies. The purpose of this study was to evaluate perioperative and late complications related to VAP implantations and to analyze factors that may predict the development of complications. PATIENTS AND METHODS: During the period 1983 to 1994, 135 VAPs were implanted in 132 patients with disseminated testicular tumors. In a retrospective study, the perioperative and late complications were recorded in this homogeneous patient group. Multivariate analysis was performed to detect factors that may predict the development of complications.
RESULTS: The median age of the patients was 28 years (range, 16 to 55). Perioperative complications were recorded in five patients (3.7%): pneumothorax in two (1.5%), blood loss in two (1.5%), and mediastinal bleeding in one (0.7%). The ports remained in situ for a total of 55,247 days (median, 413; range, 7 to 1,607). In 31 patients (23%), 42 late complications developed (31%): system obstruction in 13 (9.6%), thrombosis in 11 (8.1%), infection in six (4.4%), catheter defect in six (4.4%), extravasation in four (3.0%), and local skin necrosis in two (1.5%). Late complications were significantly more common in patients who had received chemotherapy before VAP implantation (P < .001). Univariate analysis showed that there were significantly more complications after VAP implantation under local anesthesia than under general anesthesia (P < .05).
CONCLUSION: Polychemotherapy could be administered in an adequate manner using a VAP. Complications occurred in 26.7% of a homogeneous group of patients who received a VAP implantation for polychemotherapy for disseminated testicular cancer. Chemotherapy treatment before VAP implantation was the only independent risk factor for late complications.

Entities:  

Mesh:

Year:  1996        PMID: 8918488     DOI: 10.1200/JCO.1996.14.11.2916

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

Review 1.  Extravasation of chemotherapy.

Authors:  Seppo W Langer
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 2.  Overview, prevention and management of chemotherapy extravasation.

Authors:  Firas Y Kreidieh; Hiba A Moukadem; Nagi S El Saghir
Journal:  World J Clin Oncol       Date:  2016-02-10

Review 3.  Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Authors:  Godelieve Alice Goossens; Marguerite Stas; Martine Jérôme; Philip Moons
Journal:  Support Care Cancer       Date:  2011-05-10       Impact factor: 3.603

4.  Clinical review and analysis of complications of totally implantable venous access devices for chemotherapy.

Authors:  Jung Tae Kim; Tae Yun Oh; Woon Ha Chang; Young Kyun Jeong
Journal:  Med Oncol       Date:  2011-03-06       Impact factor: 3.064

5.  Disappearance of a major thrombus in the brachiocephalic vein without anticoagulant therapy in a patient with seminoma: A case report.

Authors:  Hiroshi Hongo; Hiroki Ide; Katsura Hoshino; Yota Yasumizu; Yasumitsu Uchida; Takeshi Masuda
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

6.  Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries.

Authors:  Tim Nestler; Johannes Huber; Adrienne M Laury; Hendrik Isbarn; Axel Heidenreich; Hans U Schmelz; Christian G Ruf
Journal:  World J Urol       Date:  2018-02-07       Impact factor: 4.226

Review 7.  Oral anticancer drugs in the elderly: an overview.

Authors:  Sara Lonardi; Alberto Bortolami; Micaela Stefani; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.

Authors:  Michiel C Verboom; Jan Ouwerkerk; Neeltje Steeghs; Jacob Lutjeboer; J Martijn Kerst; Winette T A van der Graaf; Anna K L Reyners; Stefan Sleijfer; Hans Gelderblom
Journal:  Clin Sarcoma Res       Date:  2017-01-31

9.  Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.

Authors:  G V Kornek; M Raderer; B Schüll; W Fiebiger; C Gedlicka; A Lenauer; D Depisch; B Schneeweiss; F Lang; W Scheithauer
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

10.  Totally implantable venous access devices: retrospective analysis of different insertion techniques and predictors of complications in 796 devices implanted in a single institution.

Authors:  Elisa Granziera; Marco Scarpa; Angelo Ciccarese; Bogdan Filip; Matteo Cagol; Valentina Manfredi; Rita Alfieri; Connie Celentano; Sandra Cappellato; Carlo Castoro; Muzio Meroni
Journal:  BMC Surg       Date:  2014-05-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.